Who makes Linezolid dose personalization based on TDM?

Linezolid dose personalization based on TDM is developed by Marco Schiuma.

What development phase is Linezolid dose personalization based on TDM in?

Linezolid dose personalization based on TDM is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Linezolid dose personalization based on TDM

Marco Schiuma · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Linezolid dose personalization based on TDM
Sponsor	Marco Schiuma
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Linezolid dose personalization based on TDM CI brief — competitive landscape report
Linezolid dose personalization based on TDM updates RSS · CI watch RSS
Marco Schiuma portfolio CI